KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Operating Leases (2019 - 2020)

Boston Scientific's Operating Leases history spans 7 years, with the latest figure at $445.0 million for Q3 2025.

  • For Q3 2025, Operating Leases rose 19.3% year-over-year to $445.0 million; the TTM value through Sep 2025 reached $445.0 million, up 19.3%, while the annual FY2024 figure was $401.0 million, 2.82% up from the prior year.
  • Operating Leases for Q3 2025 was $445.0 million at Boston Scientific, up from $440.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $445.0 million in Q3 2025 and bottomed at $347.0 million in Q4 2022.
  • The 5-year median for Operating Leases is $389.0 million (2021), against an average of $388.3 million.
  • The largest annual shift saw Operating Leases dropped 10.8% in 2022 before it rose 19.3% in 2025.
  • A 5-year view of Operating Leases shows it stood at $389.0 million in 2021, then dropped by 10.8% to $347.0 million in 2022, then increased by 12.39% to $390.0 million in 2023, then increased by 2.82% to $401.0 million in 2024, then increased by 10.97% to $445.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Operating Leases are $445.0 million (Q3 2025), $440.0 million (Q2 2025), and $399.0 million (Q1 2025).